Text Size
1631 studies found for:    Bevacizumab

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed
Has Results 		A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
Condition: Diabetic Retinopathy
Interventions: Procedure: Laser Photocoagulation;   Drug: Bevacizumab
2 Recruiting Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome
Condition: Glaucoma
Interventions: Drug: Bevacizumab;   Drug: Mitomycin C
3 Unknown † Intralesional Bevacizumab Injection on Primary Pterygium
Conditions: Pterygium;   Inflammation
Interventions: Drug: Intralesional injection of bevacizumab;   Drug: Topical antihistamine and vasoconstrictor
4 Completed Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.
Condition: Macular Degeneration
Interventions: Drug: Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab;   Drug: Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab;   Drug: Verteporfin Photodynamic Therapy (SHAM) and bevacizumab
5 Withdrawn Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Vinorelbine;   Drug: Cisplatin;   Drug: Bevacizumab;   Drug: Docetaxel;   Drug: Gemcitabine
6 Completed Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab in Adult Patients With Kidney Cancer
Conditions: Carcinoma, Renal Cell;   Adenocarcinoma, Renal Cell;   Nephroid Carcinoma;   Carcinoma, Hypernephroid
Interventions: Drug: bevacizumab, RAD001(Everolimus);   Drug: bevacizumab, interferon alfa-2a
7 Recruiting Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
Condition: Brain Cancer
Interventions: Drug: Vorinostat;   Drug: Bevacizumab
8 Unknown † Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
Condition: Brain Tumors
Intervention: Drug: Neuradiab in combination with Bevacizumab (Avastin)
9 Recruiting Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
Conditions: Brain Neoplasms;   Central Nervous System Neoplasms
Interventions: Drug: TPI287;   Drug: Bevacizumab
10 Active, not recruiting
Has Results 		Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Conditions: Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Drug: irinotecan hydrochloride;   Biological: bevacizumab;   Drug: temozolomide
11 Terminated Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer
Condition: Toxicity
Intervention: Biological: bevacizumab
12 Recruiting Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
Conditions: Brain Cancer;   Glioblastoma
Interventions: Drug: Standard Dose Bevacizumab;   Drug: Low Dose Bevacizumab;   Drug: Lomustine
13 Recruiting HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver
Conditions: Liver Cancer;   Advanced Cancer
Interventions: Drug: Irinotecan;   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: Cetuximab
14 Recruiting Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Condition: Glioblastoma Multiforme
Interventions: Drug: Bevacizumab;   Drug: BKM120
15 Unknown † Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
Condition: Breast Cancer
Interventions: Drug: Bevacizumab 7.5 and TAC;   Drug: Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC);   Drug: Bevacizumab 15 and TAC;   Drug: Placebo 15 and TAC
16 Recruiting Efficacy and Safety Study of iSONEP With and Without Lucentis/Avastin to Treat Age-related Macular Degeneration (AMD)
Condition: Exudative Age-related Macular Degeneration
Interventions: Drug: iSONEP;   Drug: 0.5 mg iSONEP with ranibizumab or bevacizumab;   Drug: 4.0 mg iSONEP with ranibizumab or bevacizumab;   Drug: ranibizumab or bevacizumab
17 Recruiting Bevacizumab and Paclitaxel or Bevacizumab, Cyclophosphamide, and Capecitabine as First-Line Therapy in Treating Women With Locally Advanced, Recurrent, or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Biological: bevacizumab, Paclitaxel;   Biological: Bevacizumab, Cyclophosphamide, Capecitabine
18 Completed Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: bevacizumab (Avastin)
19 Recruiting Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
Condition: Adult Solid Tumor
Intervention: Drug: TRC105 and Bevacizumab
20 Active, not recruiting Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer
Condition: Non-squamous Non-small Cell Lung Cancer
Interventions: Drug: Bevacizumab + Pemetrexed;   Drug: Bevacizumab + Pemetrexed + Carboplatin
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years